<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
<journal-title-group>
<journal-title>Scientific Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-2322</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28325891</article-id>
<article-id pub-id-type="pmc">5428060</article-id>
<article-id pub-id-type="publisher-id">208</article-id>
<article-id pub-id-type="doi">10.1038/s41598-017-00208-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Whole-exome sequencing identifies a novel <italic>de novo</italic> mutation in <italic>DYNC1H1</italic> in epileptic encephalopathies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Lin</surname>
<given-names>Zhongdong</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Liu</surname>
<given-names>Zhenwei</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiucui</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Bingyu</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Zhen</given-names>
</name>
<address>
<email>yuchen6046@163.com</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Yong</given-names>
</name>
<address>
<email>liuy5599@mail.xjtu.edu.cn</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0599 1243</institution-id><institution-id institution-id-type="GRID">grid.43169.39</institution-id><institution>Institute of Neurobiology, </institution><institution>Xi’an Jiaotong University Health Science Center, </institution></institution-wrap>Xian, China </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution>Department of Pediatric Neurology, The Second Affiliated Hospital and Yuying Children’s Hospital, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, China </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution>Institute of Genomic Medicine, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, China </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1798 6507</institution-id><institution-id institution-id-type="GRID">grid.417401.7</institution-id><institution>Research Center of Blood Transfusion Medicine, Key Laboratory of Laboratory Medicine, Ministry of Education, </institution><institution>Zhejiang Provincial People’s Hospital, </institution></institution-wrap>Hangzhou, China </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>7</volume>
<elocation-id>258</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>
</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Epileptic encephalopathies (EE) are a group of severe childhood epilepsy disorders characterized by intractable seizures, cognitive impairment and neurological deficits. Recent whole-exome sequencing (WES) studies have implicated significant contribution of <italic>de novo</italic> mutations to EE. In this study, we utilized WES for identifying causal <italic>de novo</italic> mutations in 4 parent-offspring trios affected by West syndrome. As a result, we found two deleterious <italic>de novo</italic> mutations in <italic>DYNC1H1</italic> and <italic>RTP1</italic> in two trios. Expression profile analysis showed that <italic>DYNC1H1</italic> and <italic>RTP1</italic> are expressed in almost all brain regions and developmental stages. Interestingly, co-expression and genetic interaction network analyses suggested that <italic>DYNC1H1</italic> and <italic>RTP1</italic> are tightly associated with known epilepsy genes. Furthermore, we observed that the <italic>de novo</italic> mutations of <italic>DYNC1H1</italic> were identified in several different neuropsychiatric disorders including EE, autism spectrum disorders and intellectual disabilities by previous studies, and these mutations primarily occurred in the functional domain of the protein. Taken together, these results demonstrate <italic>DYNC1H1</italic> as a strong candidate and <italic>RTP1</italic> as a potential candidate on the onset of EE. In addition, this work also proves WES as a powerful tool for the molecular genetic dissection of children affected by sporadic EE.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>Epileptic encephalopathies (EE) are typically defined as a devastating group of severe childhood epilepsy disorders characterized by early onset of seizures associated with ongoing epileptic activity<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. West syndrome (MIM 308350) is one of the most common form of infantile epileptic encephalopathy, characterized by tonic spasms with clustering, arrest of psychomotor development, and hypsarrhythmia in electroencephalography (EEG)<sup><xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref></sup>. Approximately 17% of all cases can evolve into Lennox-Gastaut syndrome (LGS) which is characterized by polymorphic intractable seizures and paroxysms of fast activity in EEG<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p>
<p>In the past few years, several genes, such as <italic>ARX</italic>
<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, <italic>CDKL5</italic>
<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> and <italic>SPTAN1</italic>
<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, have been implicated in West syndrome based on a candidate gene sequencing approach<sup><xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref></sup>. Furthermore, several recent exome-sequencing studies have shown that West syndrome probands exhibit an excess of loss of function <italic>de novo</italic> mutations, which plays an important role in West syndrome<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Indeed, in a study in which exome sequencing was performed in 264 patient-parent trios with EE, <italic>de novo</italic> mutations were recurrently observed in probands within known causative genes for West syndrome, such as <italic>STXBP1</italic> (n = 4) and <italic>CDKL</italic>5 (n = 2)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. In other recent studies, <italic>de novo</italic> mutations in <italic>GRIN2B</italic>
<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, <italic>GNAO1</italic>
<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, <italic>KCNT1</italic>
<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and <italic>SPTAN1</italic>
<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> found in probands have been recognized as being associated with West syndrome. These findings showed that West syndrome is a genetically heterogeneous condition, and <italic>de novo</italic> mutations play a significant role in the onset of West syndrome.</p>
<p>Recent advances in the whole-exome sequencing (WES) approach have offered a cost-effective method for investigating single-nucleotide variants (SNVs) across all gene-coding regions in the genome. WES has been successfully applied to identify <italic>de novo</italic> mutations associated with neurodevelopmental disorders for autism spectrum disorders (ASDs)<sup><xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref></sup>, intellectual disabilities (IDs)<sup><xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref></sup>, schizophrenia (SCZ)<sup><xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref></sup> and EE<sup><xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref></sup>. To obtain insight into the characterization of <italic>de novo</italic> mutations in West syndrome, we conducted WES of 4 unrelated Chinese parent-offspring trios affected by West syndrome. The results revealed two novel <italic>de novo</italic> mutations in <italic>DYNC1H1</italic> and <italic>RTP1</italic> which were predicted to be deleterious based on the concordance of generic damage prediction tools. Furthermore, expression, co-expression and genetic interaction network analyses provided supporting evidences for the role of <italic>DYNC1H1</italic> and <italic>RTP1</italic> in EE. In particular, the <italic>de novo</italic> mutations in <italic>DYNC1H1</italic> were found to be shared among different neuropsychiatric disorders of EE, ASD and ID, which further implicated <italic>DYNC1H1</italic> in the onset of sporadic neuropsychiatric disorders.</p>
</sec>
<sec id="Sec2" sec-type="results">
<title>Results</title>
<sec id="Sec3">
<title>Detection of <italic>de novo</italic> mutations</title>
<p>WES of 4 EE trios with West syndrome (one affected child and both unaffected parents) was performed. After the removal of sequencing adapters and trimming of low-quality bases, approximately 2.12~4.72 Gb of cleaned sequencing data were obtained for each sample (Supplemental Table <xref ref-type="media" rid="MOESM1">1</xref>). More than 99.42% of the sequencing reads were aligned to the human reference genome (hg19), with 56.38% effective reads from target regions being obtained after the removal of PCR duplications. The average sequencing depth for each sample was 70.25-fold, with more than 86.00% of target regions having at least a 10-fold coverage. As a result, 21,756 SNVs or InDels were identified and 3 <italic>de novo</italic> SNVs in coding regions were identified and validated in the 4 trios. We also attempted to identify rare (new or with allele frequency &lt;0.001 based on Exome Aggregation Consortium (ExAC)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, 1000 Genomes<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and the NHLBI Exome Sequencing Project (ESP)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>) inherited mutations in known or related epilepsy genes, but no rare inherited mutations were detected for the 4 trios.</p>
</sec>
<sec id="Sec4">
<title>Analysis of the association of <italic>de novo</italic> gene mutations with EE</title>
<p>Recent WES studies based on parent-offspring trios are increasingly demonstrating that <italic>de novo</italic> mutations play a prominent role in a substantial number of EE, although the extent of this contribution is not yet known<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. In the present study, we observed that two of the three missense <italic>de novo</italic> mutations were clearly predicted to be functionally deleterious based on four mutation effect prediction tools (SIFT, VEST3, LRT and SiPhy) (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of DNMs detected by trios-based WES of EE.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Trio</th><th>Chr</th><th>Position(hg19)</th><th>Gene</th><th>Mutation</th><th>Transcript</th><th>Protein change</th><th>SIFT</th><th>VEST3</th><th>LRT</th><th>SiPhy</th></tr></thead><tbody><tr><td>E1</td><td>chr6</td><td>158318012</td><td>
<italic>SNX9</italic>
</td><td>missense</td><td>NM_016224</td><td>p.Q152K</td><td>tolerable</td><td>damaging</td><td>neutral</td><td>conserved</td></tr><tr><td>E2</td><td>chr3</td><td>186917389</td><td>
<italic>RTP1</italic>
</td><td>missense</td><td>NM_153708</td><td>p.I108N</td><td>damaging</td><td>damaging</td><td>deleterious</td><td>conserved</td></tr><tr><td>E3</td><td>chr14</td><td>102499496</td><td>
<italic>DYNC1H1</italic>
</td><td>missense</td><td>NM_001376</td><td>p.M3392V</td><td>damaging</td><td>damaging</td><td>deleterious</td><td>conserved</td></tr></tbody></table></table-wrap>
</p>
<p>One novel <italic>de novo</italic> mutation was detected in <italic>DYNC1H1</italic> in E3P proband. This mutation was nonsynonymous (c.10174A &gt; G) and caused a methionine (Met) to valine (Val) substitution at amino acid 3392 (p.M3392V) in the conserved MT domain (microtubule-binding stalk of dynein motor) (Fig. <xref ref-type="fig" rid="Fig1">1a,b</xref> and Table <xref ref-type="table" rid="Tab1">1</xref>). This mutation was predicted as deleterious by the four types of prediction tools employed in this study (Table <xref ref-type="table" rid="Tab1">1</xref>). Furthermore, <italic>DYNC1H1</italic> might be considered as an intolerant gene based on residual variation intolerance score (RVIS)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, which was developed to estimate functional variants deviations based on the ESP6500 dataset and Z score for missense variants from ExAC<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (Supplemental Table <xref ref-type="media" rid="MOESM1">2</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<italic>De novo</italic> mutations identified in <italic>DYNC1H1</italic> and <italic>RTP1</italic>. (<bold>a</bold>) The <italic>de novo</italic> mutation of <italic>DYNC1H1</italic> was confirmed in trio E3 using Sanger sequencing. (<bold>b</bold>) Schematic representation of the DYNC1H1 protein and <italic>de novo</italic> mutations of <italic>DYNC1H1</italic> identified in EE, ASD and ID. Protein changes are shown in black for ASD, green for ID and red for EE. (<bold>c</bold>) The <italic>de novo</italic> mutation of <italic>RTP1</italic> was confirmed in trio E2 using Sanger sequencing. (<bold>d</bold>) Schematic representation of the RTP1 protein and <italic>de novo</italic> mutations of <italic>RTP1</italic> identified in EE. Protein change identified in the present study is shown in red, and those identified in the previous study are shown in black.</p></caption><graphic id="d29e784" xlink:href="41598_2017_208_Fig1_HTML"></graphic></fig>
</p>
<p>We also validated a novel missense mutation of T to A substitution (c.323T &gt; A) in <italic>RTP1</italic> (MIM 609137) in E2P proband (Fig. <xref ref-type="fig" rid="Fig1">1c</xref> and Table <xref ref-type="table" rid="Tab1">1</xref>). The single nucleotide change on <italic>RTP1</italic> produced a nonsynonymous substitution (p.I108N) (Fig. <xref ref-type="fig" rid="Fig1">1d</xref>). Similarly, this mutation was considered to be deleterious according to prediction software tools (Table <xref ref-type="table" rid="Tab1">1</xref>). Although <italic>RTP1</italic> tends to be not evolutionarily constrained based on RIVS or Z score for missense from ExAC, its relatively higher haploinsufficient probability<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> indicates its functional importance (Supplemental Table <xref ref-type="media" rid="MOESM1">2</xref>). In addition to these above mentioned deleterious mutations, a single nucleotide substitution (c.454C &gt; A) on the <italic>SNX9</italic> gene (MIM 605952) was observed in a different proband, which result in an amino acid change (p.Q152K) (Supplementary Figure <xref ref-type="media" rid="MOESM1">1</xref> and Table <xref ref-type="table" rid="Tab1">1</xref>). However, this mutation was considered to be tolerable or neutral based on the predictions of the SIFT and LRT software tools, therefore, it was not considered as a possible cause.</p>
<p>Taken together, two <italic>de novo</italic> mutations in <italic>DYNC1H1</italic> and <italic>RTP1</italic> genes identified from two probands may result in severe disruption of protein function.</p>
</sec>
<sec id="Sec5">
<title>Expression profile of <italic>DYNC1H1</italic> and <italic>RTP1</italic> in the developmental human brain</title>
<p>To investigate the potential contribution of <italic>DYNC1H1</italic> and <italic>RTP1</italic> genes to human brain development and functions, we firstly assessed the expression profiles of the two genes for different brain regions and developmental stages. Gene expression levels measured using micro-arrays were obtained from the Human Brain Transcriptome database (HBT, <ext-link ext-link-type="uri" xlink:href="http://hbatlas.org/">http://hbatlas.org/</ext-link>) for 6 human brain regions, including the cerebellar cortex (CBC), mediodorsal nucleus of the thalamus (MD), striatum (STR), amygdala (AMY), hippocampus (HIP) and neocortex (NCX), and 15 human developmental periods, from early embryonic stages to late adulthood. Both <italic>DYNC1H1</italic> and <italic>RTP1</italic> were stably expressed at high levels in all 6 brain regions analyzed throughout the human lifespan (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). In addition, <italic>DYNC1H1</italic> expression was approximately two-fold higher than that of <italic>RTP1</italic>. Further analysis of the expression data for the two genes in 11 areas of the neocortex region based on the HBT database revealed similar expression patterns in 6 different brain regions (Supplementary Figure <xref ref-type="media" rid="MOESM1">2</xref>). Therefore, we concluded that <italic>DYNC1H1</italic> and <italic>RTP1</italic> may be important for early brain development and normal brain functions considering their stable high expression levels, and are potential candidate genes for brain function related disorders.<fig id="Fig2"><label>Figure 2</label><caption><p>Expression analysis of <italic>DYNC1H1</italic> and <italic>RTP1</italic> in six human brain regions. Expression profiles are shown for <italic>DYNC1H1</italic> (<bold>a</bold>) and <italic>RTP1</italic> (<bold>b</bold>). The expression levels of <italic>DYNC1H1</italic> and <italic>RTP1</italic> are shown for the developmental stages from the embryonic development stage at 50 days to late adulthood (e.g., 30,000 days). A solid line between periods 7 and 8 separates prenatal periods from postnatal periods. CBC, cerebellar cortex; MD, mediodorsal nucleus of the thalamus; STR, striatum; AMY, amygdala; HIP, hippocampus; NCX, neocortex.</p></caption><graphic id="d29e919" xlink:href="41598_2017_208_Fig2_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec6">
<title>Co-expression and genetic interaction network analyses of <italic>DYNC1H1</italic> and <italic>RTP1</italic></title>
<p>To further explore the relationship of <italic>DYNC1H1</italic> and <italic>RTP1</italic> expression with other genes related to epilepsy, we performed a co-expression network analysis based on gene expression data for the human brain throughout development from the BrainSpan database (<ext-link ext-link-type="uri" xlink:href="http://www.brainspan.org/">http://www.brainspan.org/</ext-link>). An obvious co-expression relationship was observed between each of the two genes and epilepsy-associated genes obtained from the EpilepsyGene database (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). <italic>DYNC1H1</italic> was co-expressed (Pearson correlation coefficients ≥0.6) with 46 associated epilepsy genes among all co-expressed genes (significance p = 6.6 × 10<sup>−4</sup>, Fisher’s exact test), and in addition, 15 genes (significance p = 0.024, Fisher’s exact test) were considered high-confidence genes based on their relevance to epilepsy according to gene prioritization in the EpilepsyGene database (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). In addition, we detected a co-expression relationship between <italic>RTP1</italic> and 17 genes associated with epilepsy (significance p = 0.025, Fisher’s exact test), almost half of which belong to the high-confidence genes (significance p = 0.012, Fisher’s exact test).<fig id="Fig3"><label>Figure 3</label><caption><p>Co-expression network analysis of <italic>DYNC1H1</italic> and <italic>RTP1</italic>. Gene co-expression levels were estimated using the Pearson correlation coefficients (r) between each pair of genes. Candidate epilepsy genes were extracted from the EpilepsyGene database.</p></caption><graphic id="d29e972" xlink:href="41598_2017_208_Fig3_HTML"></graphic></fig>
</p>
<p>Furthermore, to investigate the functional association between the two genes and other genes associated with epilepsy, we implemented a genetic interactions network analysis based on the interaction dataset collected from the GeneMANIA database. The results revealed that <italic>DYNC1H1</italic> was associated with 41 epilepsy-associated genes obtained from the EpilepsyGene database to different extents (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Similarly, <italic>RTP1</italic> displayed genetic interactions with 22 genes. Within this genetic interaction network, 12 high-confidence genes associated with epilepsy were detected in the network analysis of <italic>DYNC1H1</italic>, in addition to 9 genes for <italic>RTP1</italic> (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Furthermore, five shared genes existed between the genetic interaction networks for <italic>DYNC1H1</italic> and <italic>RTP1</italic>. In particular, <italic>CBL</italic> and <italic>KCNQ3</italic>, two shared genes, were considered high-confidence genes associated with epilepsy (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Overall, the co-expression and genetic interactions network analyses indicated that <italic>DYNC1H1</italic> and <italic>RTP1</italic> may share a similar role with several candidate epilepsy genes.<fig id="Fig4"><label>Figure 4</label><caption><p>Genetic interaction network analysis of <italic>DYNC1H1</italic> and <italic>RTP1</italic>. A node represents genes, and an edge represents interactions between each pair of genes. Candidate epilepsy genes were extracted from the EpilepsyGene database.</p></caption><graphic id="d29e1031" xlink:href="41598_2017_208_Fig4_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec7" sec-type="discussion">
<title>Discussion</title>
<p>The <italic>DYNC1H1</italic> gene is located in chromosome 14q32 and was previously implicated in both central and peripheral neuronal dysfunction<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, associated with syndromes involving spinal nerve degeneration and brain developmental problems<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. In a previous study, frequent recurrence of mutations in <italic>DYNC1H1</italic> (8 different <italic>de novo</italic> mutations in 16 unrelated probands) was described in a cohort of individuals affected by the malformations of cortical development (MCD) disorder using WES<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Interestingly, among the probands with <italic>de novo</italic> mutations in the <italic>DYNC1H1</italic> gene, one proband had clinical symptoms of EE (LGS), and 4 additional probands also possessed epileptic features. Another recent study reported a novel <italic>de novo</italic> mutation in <italic>DYNC1H1</italic> presenting with the clinical phenotype of sporadic congenital Spinal Muscular Atrophy-Lower Extremity Dominant (SMA-LED) and EE<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. In addition, the DYNC1H1 gene tends to be intolerant to functional genetic variation based on RIVS and Z score for missense from ExAC. Furthermore, the detected <italic>de novo</italic> mutation (c.10174A &gt; G, p.M3392V) in DYNC1H1 was predicted as “deleterious” based on multiple bioinformatics algorithms and was not observed in any large control population variation databases, including ExAC, 1000 Genomes, dbSNP 142 and ESP databases. These observations suggested that the <italic>de novo</italic> mutation in <italic>DYNC1H1</italic> may play an important role in EE.</p>
<p>Notably, <italic>de novo</italic> mutations in the <italic>DYNC1H1</italic> are recurrently detected based on WES studies in probands with different sporadic neuropsychiatric disorders, such as EE, ID and ASD<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. In a recent study, in 2 unrelated patients with severe ID syndromes, 2 different <italic>de novo</italic> mutations were identified in the <italic>DYNC1H1</italic> gene (Fig. <xref ref-type="fig" rid="Fig1">1b</xref> and Table <xref ref-type="table" rid="Tab2">2</xref>)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Notably, one 51-year-old patient with severe ID who developed generalized epileptic seizures at the age of 3 years<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Moreover, other 6 different nonsynonymous <italic>de novo</italic> mutations were detected in <italic>DYNC1H1</italic> in 6 different trios from 3 different cohorts associated with ASD (Fig. <xref ref-type="fig" rid="Fig1">1b</xref> and Table <xref ref-type="table" rid="Tab2">2</xref>)<sup><xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref></sup>. Indeed, the shared genetic etiology between EE and other neuropsychiatric disorders, including ASD, and ID, has previously been described<sup><xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref></sup>. These results suggest that the <italic>de novo</italic> mutations of <italic>DYNC1H1</italic> are shared among EE, ASD and ID, which indicate its possible contribution to these different genetic disorders.<table-wrap id="Tab2"><label>Table 2</label><caption><p>The shared <italic>de novo</italic> mutations of <italic>DYNC1H1</italic> among ASD, ID and EE.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chr</th><th>Mutation</th><th>Protein change</th><th>Mutation type</th><th>Disorder</th><th>Method</th><th>Reference</th></tr></thead><tbody><tr><td>Chr14</td><td>c.2467G &gt; T</td><td>p.Val823Leu</td><td>SNV</td><td>ASD</td><td>WES</td><td>Rubeis S <italic>et al.</italic> Nature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.6698C &gt; T</td><td>p.Ala2233Val</td><td>SNV</td><td>ASD</td><td>WES</td><td>Rubeis S <italic>et al.</italic> Nature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.7718A &gt; G</td><td>p.Asp2573Gly</td><td>SNV</td><td>ASD</td><td>WES</td><td>Rubeis S <italic>et al.</italic> Nature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.12797A &gt; T</td><td>p.Asn4266Ile</td><td>SNV</td><td>ASD</td><td>WES</td><td>Rubeis S <italic>et al.</italic> Nature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.12214G &gt; A</td><td>p.Gly4072Ser</td><td>SNV</td><td>ASD</td><td>WES</td><td>Iossifov I <italic>et al.</italic> Nature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.925C &gt; T</td><td>p.Arg309Cys</td><td>SNV</td><td>ASD</td><td>WES</td><td>Krumm N <italic>et al.</italic> Nat Genet<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.11465A &gt; C</td><td>p.His3822Pro</td><td>SNV</td><td>ID</td><td>WES</td><td>Willemsen MH <italic>et al.</italic> J Med Genet<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.4552C &gt; T</td><td>p. Glu1518 Lys</td><td>SNV</td><td>ID</td><td>WES</td><td>Willemsen MH <italic>et al.</italic> J Med Genet<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>
</td></tr><tr><td>Chr14</td><td>c.10174A &gt; G</td><td>p.Met3392Val</td><td>SNV</td><td>EE</td><td>WES</td><td>In this study</td></tr></tbody></table></table-wrap>
</p>
<p>According to previous research, most of the <italic>de novo</italic> mutations in <italic>DYNC1H1</italic> were identified in functional domains in ASD, ID and EE<sup><xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref></sup>, with the exception of one variant in ID (c.11465A &gt; C, p.H3822P) and one variant in ASD (c.12797A &gt; T, p.N4266I). These results indicate that these domains play an important role in the function of <italic>DYNC1H1</italic>. The <italic>de novo</italic> Met3392Val mutation in <italic>DYNC1H1</italic> identified in this study is located in the stalk domain derived from two of the coiled-coil domains and is considered to maintain dynein function and neuronal physiology. Four unrelated patients with MCD disorder carrying <italic>de novo</italic> mutations in the stalk domain and showing obvious clinical symptoms of EE and early onset epilepsy were recently reported<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. This finding indicated that disruption of the stalk domain might affect cortical development associated with the occurrence of epilepsy. We are unsure about the exact mechanisms for different genetics variants in <italic>DYNC1H1</italic> underlying the different phenotypes as mentioned above. However, location and nature of the different mutations, genetic background, and other complex factors including environmental influence, mutation timing and epigenetic factors could affect the genotype to phenotype relationship<sup><xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
<p>One deleterious <italic>de novo</italic> missense mutation (c.323T &gt; A) in the <italic>RTP1</italic> gene was identified in another proband. <italic>RTP1</italic> encodes a member of the receptor transporter protein family and can specifically induce functional cell surface expression of odorant receptors in human embryonic kidney cells<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Thus far, this gene has not been clearly associated with any neurodevelopmental disorder according to our knowledge. Nevertheless, one <italic>de novo</italic> mutation (c.334A &gt; G; p.M112V) in <italic>RTP1</italic> was recently described in an EE proband in a cohort of 264 trios based on WES<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Although <italic>RTP1</italic> does not tend to be evolutionarily constrained based on RIVS or Z score for missense variant from ExAC, RTP1 is most likely a haploinsufficient gene. Furthermore, this mutation in <italic>RTP1</italic> (c.323T &gt; A) was not observed in any large control population through searching public variation database including ExAC, ESP and 1000 Genomes. These observations indicated that <italic>RTP1</italic> may be a potential candidate gene for EE.</p>
<p>In recent years, WES has proved to be an efficient diagnostic approach for Mendelian diseases<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. However, some limitations in WES technique impede high-efficiency detection for INDELs and CNVs, and <italic>de novo</italic> mutations from noncoding regions of UTR, introns, or intergenic regions, and synonymous mutations are usually ignored<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. In addition, for some GC-rich regions, it is difficult to obtain effective sequencing coverage and depth of sequencing for variant detection<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. These factors are likely to prevent the detection of possible deleterious mutations. The solution of these problems generally includes algorithm improvement, increase of read depth in target regions and application of whole-genome sequencing (WGS)<sup><xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref></sup>. Nevertheless, it should be noted that approximately 85% of known disease-causing variants are in the coding regions<sup><xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref></sup>. WES still represents a powerful tool for diagnosis and is adopted by many studies<sup><xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
</sec>
<sec id="Sec8">
<title>Methods</title>
<sec id="Sec9">
<title>Patient recruitment</title>
<p>We collected samples from 4 unrelated West syndrome trios of Han Chinese ancestry from the Second Affiliated Hospital &amp; Yuying Children’s Hospital of Wenzhou Medical University. This study protocol was approved by the Hospital Ethics Committee, and was carried out in accordance with the approved guidelines. Written informed consent was obtained from all participants or their caregivers prior to peripheral blood and clinical data collection. These cases comprised 3 males and 1 females with obvious clinical symptoms of West syndrome, characterized by refractory seizures and cognitive arrest or regression. All epilepsy diagnoses were evaluated based on an assessment of clinical seizure presentation and EEG recorded by a pediatric neurologist with experience in the clinical diagnosis of epileptic encephalopathies.</p>
</sec>
<sec id="Sec10">
<title>Whole-exome sequencing</title>
<p>Genomic DNA samples were extracted from 1 ml of peripheral blood leukocytes obtained from the parents and probands using the QIAGEN DNeasy Blood &amp; Tissue Kit (Qiagen, Valencia, CA, USA). DNA quality and quantity were assessed using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Approximately 2 µg of high-quality genomic DNA from each sample was prepared as the starting material for generating the sequencing library using the Agilent SureSelect Library Prep Kit according to the manufacturer’s instructions. Through target enrichment of DNA samples and construction of a hybridization library, the whole exome was captured using the Agilent SureSelect Human All Exon v5 Kit (Agilent Technologies, Santa Clara, CA, USA). In addition, all sheared DNA samples were tagged through PCR using an index (barcode) sequence. After the purification and quality assessment of the sample libraries, the samples were pooled according to mass, followed by multiplex sequencing using an Illumina HiSeq2000 sequencer (San Diego, CA, USA.) with 101 bp paired-end reads.</p>
</sec>
<sec id="Sec11">
<title>Data processing and <italic>de novo</italic> mutation detection</title>
<p>The raw sequencing reads generated through WES for the 12 individual samples were processed to remove sequence adapters and low-quality reads using the Trim_Galore program. Only sequencing reads with Phred-scaled quality scores greater than 30 and read lengths greater than 80 bp were retained for further analysis. The sequencing reads were aligned to the human reference genome (GRCH37/hg19) using the BWA program (version 0.7.12). After read mapping, duplicated reads and reads mapped to multiple genome locations were removed with the Picard software tool. GATK tools were used for the read realignment, quality score recalibration and SNP/InDel variant calling. Two software tools (ForestDNM and mirTrios) were used for <italic>de novo</italic> mutation detection, and mutations indicated to be <italic>de novo</italic> using both tools were considered as reliable <italic>de novo</italic> mutations for further analysis in the present study.</p>
</sec>
<sec id="Sec12">
<title><italic>De novo</italic> mutation annotation and evaluation of the tolerance of genes</title>
<p>All variants were annotated using the ANNOVAR software tool and in-house codes. The consequences of mutations for protein products were inferred based on RefSeq gene annotations (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/refseq/">http://www.ncbi.nlm.nih.gov/refseq/</ext-link>). Functional predictions for missense variants were obtained using 4 software tools: SIFT, LRT, SiPhy, and VEST3. A missense variant was considered deleterious based on the concordance of four generic damage prediction tools. For each sequence variant, the allele frequency (AF) was obtained from normal population variant databases, including dbSNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>), 1000 Genomes (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>), ESP6500 (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), ExAC (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>), CG69 (<ext-link ext-link-type="uri" xlink:href="http://www.completegenomics.com/public-data/69-genomes/">http://www.completegenomics.com/public-data/69-genomes/</ext-link>) and GWAS Catalog (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/gwas/">https://www.ebi.ac.uk/gwas/</ext-link>). Variants with AF &lt;0.001 according to 1000 Genomes, ESP6500 and ExAC were defined as rare variants.</p>
<p>To assess the intolerance of genes to functional genetic variation, we utilized the predicted haploinsufficient probability<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, residual variation intolerance score (RVIS) based on the ESP6500<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> dataset and Z score for missense variants from ExAC<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p>
</sec>
<sec id="Sec13">
<title>Primers and Sanger sequencing validation</title>
<p>To validate each potential <italic>de novo</italic> mutation detected in the present study, 100 ng of genomic DNA from each sample was used to amplify the target mutation region through conventional PCR and Sanger sequencing. All primers in these assays are listed in Supplemental Table <xref ref-type="media" rid="MOESM1">3</xref>.</p>
</sec>
<sec id="Sec14">
<title>Gene co-expression and genetic interaction network</title>
<p>Gene expression data were obtained from the BrainSpan (<ext-link ext-link-type="uri" xlink:href="http://www.brainspan.org/">http://www.brainspan.org/</ext-link>) database, which shows gene expression levels for specific brain regions obtained through RNA sequencing and exon microarray techniques. Gene co-expression levels were estimated based on the Pearson correlation coefficients (r) between each pair of genes. We extracted each pair of genes exhibiting high co-expression correlation coefficient (absolute r ≥ 0.6) compared with target genes and candidate epilepsy genes in the EpilepsyGene database<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Enrichment analysis of co-expressed epilepsy genes by using one-sided Fisher’s Exact test. To generate a human genetic interaction network, the direct protein-protein interaction dataset was collected from GeneMANIA<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, based on the InWeb database or the Cytoscape program plugin<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. In addition, GeneMANIA was employed to calculate the number of nodes and edges between the target genes and candidate epilepsy genes from the EpilepsyGene database. In the genetic interaction network, a node represents genes, and an edge represents interactions between two genes. The thickness of the edge represents the degree of genetic interaction. Both gene co-expression and the genetic interaction network were visualized using the Cytoscape program.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec15">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2017_208_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>Zhongdong Lin and Zhenwei Liu contributed equally to this work.</p>
</fn>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>
<bold>Supplementary information</bold> accompanies this paper at doi:10.1038/s41598-017-00208-6
</p>
</fn>
<fn>
<p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>This work was financially supported through grants from the National Natural Science Foundation of China (31401110/C060605 and 81501824), and Natural Science Foundation of Zhejiang Province (LY15C090004).</p>
</ack>
<notes notes-type="author-contribution">
<title>Author Contributions</title>
<p>Z.D.L., Z.W.L., Z.W. and Y.L. designed the experiments; Z.D.L., X.C.L. and F.L. performed the experiments; Z.W.L. Y.H. and B.Y.C. analyzed the data; F.L. and Z.W. contributed reagents/materials/analysis tools; Z.D.L., Z.W.L., and Y.L. contributed to the writing of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Competing Interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McTague</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kurian</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
</person-group>
<article-title>The genetic landscape of the epileptic encephalopathies of infancy and childhood</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<volume>15</volume>
<fpage>304</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00250-1</pub-id>
<pub-id pub-id-type="pmid">26597089</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome)</article-title>
<source/>Am J Hum Genet
          <year>2007</year>
<volume>81</volume>
<fpage>361</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1086/518903</pub-id>
<pub-id pub-id-type="pmid">17668384</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caraballo</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients</article-title>
<source/>Seizure
          <year>2011</year>
<volume>20</volume>
<fpage>640</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2011.06.009</pub-id>
<pub-id pub-id-type="pmid">21763159</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stromme</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy</article-title>
<source/>Nat Genet
          <year>2002</year>
<volume>30</volume>
<fpage>441</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1038/ng862</pub-id>
<pub-id pub-id-type="pmid">11889467</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weaving</surname>
<given-names>LS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation</article-title>
<source/>Am J Hum Genet
          <year>2004</year>
<volume>75</volume>
<fpage>1079</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1086/426462</pub-id>
<pub-id pub-id-type="pmid">15492925</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitsu</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay</article-title>
<source/>Am J Hum Genet
          <year>2010</year>
<volume>86</volume>
<fpage>881</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.04.013</pub-id>
<pub-id pub-id-type="pmid">20493457</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamien</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Cardamone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A genetic diagnostic approach to infantile epileptic encephalopathies</article-title>
<source/>J Clin Neurosci
          <year>2012</year>
<volume>19</volume>
<fpage>934</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1016/j.jocn.2012.01.017</pub-id>
<pub-id pub-id-type="pmid">22617547</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paciorkowski</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Thio</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>Genetic and biologic classification of infantile spasms</article-title>
<source/>Pediatr Neurol
          <year>2011</year>
<volume>45</volume>
<fpage>355</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2011.08.010</pub-id>
<pub-id pub-id-type="pmid">22114996</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>AS</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo</italic> mutations in epileptic encephalopathies</article-title>
<source/>Nature
          <year>2013</year>
<volume>501</volume>
<fpage>217</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature12439</pub-id>
<pub-id pub-id-type="pmid">23934111</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemke</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>75</volume>
<fpage>147</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24073</pub-id>
<pub-id pub-id-type="pmid">24272827</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De Novo</italic> mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy</article-title>
<source/>Am J Hum Genet
          <year>2013</year>
<volume>93</volume>
<fpage>496</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2013.07.014</pub-id>
<pub-id pub-id-type="pmid">23993195</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohba</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo</italic> KCNT1 mutations in early-onset epileptic encephalopathy</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>e121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13072</pub-id>
<pub-id pub-id-type="pmid">26140313</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Writzl</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early onset West syndrome with severe hypomyelination and coloboma-like optic discs in a girl with SPTAN1 mutation</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<fpage>e106</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03437.x</pub-id>
<pub-id pub-id-type="pmid">22429196</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kornblum</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Papazian</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>SF</given-names>
</name>
</person-group>
<article-title>Exome sequencing identifies <italic>de novo</italic> gain of function missense mutation in KCND2 in identical twins with autism and seizures that slows potassium channel inactivation</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>3481</fpage>
<lpage>3489</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu056</pub-id>
<pub-id pub-id-type="pmid">24501278</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of <italic>de novo</italic> coding mutations to autism spectrum disorder</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature13908</pub-id>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissers</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A <italic>de novo</italic> paradigm for mental retardation</article-title>
<source/>Nat Genet
          <year>2010</year>
<volume>42</volume>
<fpage>1109</fpage>
<lpage>1112</lpage>
<pub-id pub-id-type="doi">10.1038/ng.712</pub-id>
<pub-id pub-id-type="pmid">21076407</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Ligt</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>
<source/>N Engl J Med
          <year>2012</year>
<volume>367</volume>
<fpage>1921</fpage>
<lpage>1929</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id>
<pub-id pub-id-type="pmid">23033978</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing supports a <italic>de novo</italic> mutational paradigm for schizophrenia</article-title>
<source/>Nat Genet
          <year>2011</year>
<volume>43</volume>
<fpage>864</fpage>
<lpage>868</lpage>
<pub-id pub-id-type="doi">10.1038/ng.902</pub-id>
<pub-id pub-id-type="pmid">21822266</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo</italic> mutations in schizophrenia implicate synaptic networks</article-title>
<source/>Nature
          <year>2014</year>
<volume>506</volume>
<fpage>179</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1038/nature12929</pub-id>
<pub-id pub-id-type="pmid">24463507</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nava</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo</italic> mutations in HCN1 cause early infantile epileptic encephalopathy</article-title>
<source/>Nat Genet
          <year>2014</year>
<volume>46</volume>
<fpage>640</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2952</pub-id>
<pub-id pub-id-type="pmid">24747641</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veeramah</surname>
<given-names>KR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing reveals new causal mutations in children with epileptic encephalopathies</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1270</fpage>
<lpage>1281</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12201</pub-id>
<pub-id pub-id-type="pmid">23647072</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>
<source/>Nature
          <year>2016</year>
<volume>536</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genomes Project</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A global reference for human genetic variation</article-title>
<source/>Nature
          <year>2015</year>
<volume>526</volume>
<fpage>68</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1038/nature15393</pub-id>
<pub-id pub-id-type="pmid">26432245</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hildebrand</surname>
<given-names>MS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recent advances in the molecular genetics of epilepsy</article-title>
<source/>J Med Genet
          <year>2013</year>
<volume>50</volume>
<fpage>271</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101448</pub-id>
<pub-id pub-id-type="pmid">23468209</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrovski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Heinzen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>Genic intolerance to functional variation and the interpretation of personal genomes</article-title>
<source/>PLoS Genet
          <year>2013</year>
<volume>9</volume>
<fpage>e1003709</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003709</pub-id>
<pub-id pub-id-type="pmid">23990802</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Marcotte</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hurles</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Characterising and predicting haploinsufficiency in the human genome</article-title>
<source/>PLoS Genet
          <year>2010</year>
<volume>6</volume>
<fpage>e1001154</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1001154</pub-id>
<pub-id pub-id-type="pmid">20976243</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in DYNC1H1 cause severe intellectual disability with neuronal migration defects</article-title>
<source/>J Med Genet
          <year>2012</year>
<volume>49</volume>
<fpage>179</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100542</pub-id>
<pub-id pub-id-type="pmid">22368300</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorillo</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel dynein DYNC1H1 neck and motor domain mutations link distal spinal muscular atrophy and abnormal cortical development</article-title>
<source/>Hum Mutat
          <year>2014</year>
<volume>35</volume>
<fpage>298</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22491</pub-id>
<pub-id pub-id-type="pmid">24307404</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poirier</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>639</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2613</pub-id>
<pub-id pub-id-type="pmid">23603762</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Spinal Muscular Atrophy-Lower Extremity Dominant (SMA-LED), with bilateral perisylvian polymicrogyria and infantile epileptic encephalopathy, due a novel DYNC1H1 mutation</article-title>
<source/>Neuromuscular Disorders
          <year>2015</year>
<volume>25</volume>
<fpage>S222</fpage>
<lpage>S223</lpage>
<pub-id pub-id-type="doi">10.1016/j.nmd.2015.06.139</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Paciorkowski</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder and epilepsy: Disorders with a shared biology</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>47</volume>
<fpage>191</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.03.017</pub-id>
<pub-id pub-id-type="pmid">25900226</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess of rare, inherited truncating mutations in autism</article-title>
<source/>Nat Genet
          <year>2015</year>
<volume>47</volume>
<fpage>582</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3303</pub-id>
<pub-id pub-id-type="pmid">25961944</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rubeis</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>209</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1038/nature13772</pub-id>
<pub-id pub-id-type="pmid">25363760</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Mantilla</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders</article-title>
<source/>JAMA Psychiatry
          <year>2016</year>
<volume>73</volume>
<fpage>275</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.2692</pub-id>
<pub-id pub-id-type="pmid">26817790</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genes with <italic>de novo</italic> mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>290</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.40</pub-id>
<pub-id pub-id-type="pmid">25849321</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<mixed-citation publication-type="other">Guo, S. <italic>et al</italic>. Identification of Novel Compound Mutations in PLA2G6-Associated Neurodegeneration Patient with Characteristic MRI Imaging. <italic>Mol Neurobiol</italic> (2016).</mixed-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miceli</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K(v)7.2 potassium channel subunits</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2013</year>
<volume>110</volume>
<fpage>4386</fpage>
<lpage>4391</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1216867110</pub-id>
<pub-id pub-id-type="pmid">23440208</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>El-Osta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blumcke</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>The methylation hypothesis of pharmacoresistance in epilepsy</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<issue>Suppl 2</issue>
<fpage>41</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12183</pub-id>
<pub-id pub-id-type="pmid">23646970</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zweier</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila</article-title>
<source/>Am J Hum Genet
          <year>2009</year>
<volume>85</volume>
<fpage>655</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2009.10.004</pub-id>
<pub-id pub-id-type="pmid">19896112</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Matsunami</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>RTP family members induce functional expression of mammalian odorant receptors</article-title>
<source/>Cell
          <year>2004</year>
<volume>119</volume>
<fpage>679</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2004.11.021</pub-id>
<pub-id pub-id-type="pmid">15550249</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fogel</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Satya-Murti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Clinical exome sequencing in neurologic disease</article-title>
<source/>Neurol Clin Pract
          <year>2016</year>
<volume>6</volume>
<fpage>164</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1212/CPJ.0000000000000239</pub-id>
<pub-id pub-id-type="pmid">27104068</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetreault</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bareke</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nadaf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alirezaie</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Majewski</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities</article-title>
<source/>Expert Rev Mol Diagn
          <year>2015</year>
<volume>15</volume>
<fpage>749</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="pmid">25959410</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Exome sequencing greatly expedites the progressive research of Mendelian diseases</article-title>
<source/>Front Med
          <year>2014</year>
<volume>8</volume>
<fpage>42</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1007/s11684-014-0303-9</pub-id>
<pub-id pub-id-type="pmid">24384736</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>JX</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities</article-title>
<source/>Am J Hum Genet
          <year>2015</year>
<volume>97</volume>
<fpage>199</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.06.009</pub-id>
<pub-id pub-id-type="pmid">26166479</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahdieh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>An overview of mutation detection methods in genetic disorders</article-title>
<source/>Iran J Pediatr
          <year>2013</year>
<volume>23</volume>
<fpage>375</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">24427490</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ran</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EpilepsyGene: a genetic resource for genes and mutations related to epilepsy</article-title>
<source/>Nucleic Acids Res
          <year>2015</year>
<volume>43</volume>
<fpage>D893</fpage>
<lpage>899</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku943</pub-id>
<pub-id pub-id-type="pmid">25324312</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warde-Farley</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function</article-title>
<source/>Nucleic Acids Res
          <year>2010</year>
<volume>38</volume>
<fpage>W214</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkq537</pub-id>
<pub-id pub-id-type="pmid">20576703</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoot</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ruscheinski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Ideker</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Cytoscape 2.8: new features for data integration and network visualization</article-title>
<source/>Bioinformatics
          <year>2011</year>
<volume>27</volume>
<fpage>431</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btq675</pub-id>
<pub-id pub-id-type="pmid">21149340</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>